Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26649948 | 0.92 | LMNA (0.52) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL26648126 | 0.92 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL4067507 | 0.92 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL26833137 | 0.91 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL6943486 | 0.90 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL26648035 | 0.87 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL18673 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL3963428 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL19996569 | 0.87 | ALDH1A1 (0.74) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL18686247 | 0.87 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250186591-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12251445-B2 | Gamma-hydroxybutyrate delivering compounds and processes for making and using them | ZEVRA THERAPEUTICS, INC. | 2025-03-18 | — | — | US | disclosed |
| EP-4511354-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | Zevra Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511353-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | Zevra Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511121-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | Zevra Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511122-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | Zevra Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023205241-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023205245-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-0973768-B1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6583164-B1 | Lyophilized imidazole-1-yl or 1,2,4-triazole-1-yl quaternized with a alklycarbonyloxy alkyl group eliminated in vivo; a saccharide; 4-acetoxymethyl-1-(3-(2-oxo-3-(4-(1H-tetrazol-yl) phenyl)-1-imidazolydinyl)butyl)-1H-1,2,4-triazolium chloride | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-6407129-B1 | INJECTABLE QUATERNIZED SALT FUNGICIDES; WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1120116-A1 | ANTIMYCOTIC DRUG COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186591-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | ALDH1A1 300/4885MAPK1 4721/4885L3MBTL1 2681/4885 |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | ALDH1A1 344/4885MAPK1 4660/4885L3MBTL1 3004/4885 |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | ALDH1A1 300/4885MAPK1 4721/4885L3MBTL1 2681/4885 |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | ALDH1A1 300/4885MAPK1 4721/4885L3MBTL1 2681/4885 |
| US-12251445-B2 | Gamma-hydroxybutyrate delivering compounds and processes for making and using them | HSD17B10, HSD17B12, HSD17B14 | ALDH1A1 300/4885MAPK1 4721/4885L3MBTL1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.